In addition, natural product derivative Midostaurin (Figure 1C) has been approved by the US FDA for the treatment of FLT3-mutated acute myelogenous leukemia (AML) [11], and synthetic indolocarbazole derivative D (Figure 1D) shows excellent antibacterial activity and good antifungal activity [12]. The gene discussed is FLT3; the disease is acute myeloid leukemia.